Elevated MIA levels in the serum of pregnant women and of children

Clinical and Experimental Dermatology

Volumn 29, Issue 6, 2004, Pages 628-629

  Bosserhoff, A K ^a   Kuster H ^b   Hein, Rüdiger ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN MIA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CARTILAGE CELL; CHILD; CHILD GROWTH; CHILDHOOD; CONTROLLED STUDY; FEMALE; HUMAN; MELANOMA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THIRD TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; AGING; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; INFANT; MELANOMA; NEOPLASM PROTEINS; PREGNANCY; PREGNANCY PROTEINS; PROTEINS; REFERENCE VALUES; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 9644290704     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01623.x     Document Type: Article

References (10)

1. Bosserhoff AK, Kaufmann M, Kaluza B et al. MIA, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-53.
2. Deichmann M, Benner A, Bock M et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891-6.
3. Djukanovic D, Hofmann U, Sucker A et al. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20; 2203-7.
4. Dréau D, Bosserhoff AK, White RL et al. Melanoma-inhibitory activity protein, a useful marker to monitor melanoma patients treated with immunotherapy. Oncol Res 1999; 11: 55-61.
5. Juergensen A, Holzapfel U, Hein R et al. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 2001; 22: 54-8.
6. Schmitz C, Brenner W, Henze E et al. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000; 20: 5059-63.
7. Neidhart M, Muller-Ladner U, Frey W, Bosserhoff AK et al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000; 8: 222-9.
8. Muller-Ladner U, Bosserhoff AK, Dreher K et al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 148-54.
9. Dietz UH, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 1996; 271: 3311-6.
10. Bosserhoff AK, Kondo S, Moser M et al. Mouse CD-RAP/ MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 1997; 208: 516-25.